Biolase, Inc. short interest in 2018
In 2018, Biolase, Inc.'s disclosed short interest ran from 2.48% of shares outstanding on 12 Jan 2018 to 2.04% on 31 Dec 2018, a change of -0.44 percentage points. The year's high was 2.50% on 15 Feb 2018 and its low 1.62% on 15 Oct 2018, averaging 1.94% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 31.58 days on 28 Feb 2018. Full history: Biolase, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023
2018 in figures
- Start of year
- 2.48% (12 Jan 2018)
- End of year
- 2.04% (31 Dec 2018)
- Change
- -0.44 pp
- High
- 2.50% (15 Feb 2018)
- Low
- 1.62% (15 Oct 2018)
- Average
- 1.94%
- Highest days to cover
- 31.58 (28 Feb 2018)
- SEC filings marked
- 8
Every report in 2018
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2018 | 2.48% | 7.99 | |
| 31 Jan 2018 | 2.44% | 8.13 | |
| 15 Feb 2018 | 2.50% | 19.96 | |
| 28 Feb 2018 | 2.47% | 31.58 | |
| 15 Mar 2018 | 1.77% | 10.86 | 10-K filed, results (8-K) |
| 29 Mar 2018 | 1.72% | 17.94 | |
| 13 Apr 2018 | 1.72% | 11.35 | |
| 30 Apr 2018 | 1.73% | 17.15 | |
| 15 Aug 2018 | 1.74% | 6.49 | results (8-K), 10-Q filed, results (8-K), 10-Q filed |
| 31 Aug 2018 | 1.67% | 5.51 | |
| 14 Sep 2018 | 1.92% | 3.73 | |
| 28 Sep 2018 | 1.84% | 6.65 | |
| 15 Oct 2018 | 1.62% | 4.33 | |
| 31 Oct 2018 | 1.74% | 24.81 | |
| 15 Nov 2018 | 1.78% | 16.63 | results (8-K), 10-Q filed |
| 30 Nov 2018 | 1.85% | 6.33 | |
| 14 Dec 2018 | 1.93% | 11.32 | |
| 31 Dec 2018 | 2.04% | 4.99 |
See also: Biolase, Inc.'s full history · most shorted US stocks of 2018 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.